PharmGen Science, Inc. (KRX:004720)
South Korea · Delayed Price · Currency is KRW 4,070.00
-15.00 (-0.37%)
Feb 19, 2026, 11:00 AM KST
PharmGen Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 117.75 | 2,791 | 6,089 | 70,060 | 32,466 | 9,222 |
Depreciation & Amortization | 4,628 | 4,636 | 4,247 | 3,371 | 3,142 | 2,963 |
Loss (Gain) From Sale of Assets | 16.83 | 16.83 | -46.35 | -1.94 | 11.49 | 29.13 |
Asset Writedown & Restructuring Costs | - | - | 228.3 | 133.08 | 799.9 | 53.75 |
Loss (Gain) From Sale of Investments | 3,061 | 3,061 | -51.6 | -9.77 | -1.11 | 1,085 |
Loss (Gain) on Equity Investments | 7,355 | 4,916 | 2,539 | -87,213 | -46,633 | -14,508 |
Stock-Based Compensation | - | - | - | - | 4,359 | 1,671 |
Provision & Write-off of Bad Debts | 96.01 | 195.85 | -125.07 | -289.72 | 5.11 | 1,243 |
Other Operating Activities | -279.54 | 950.05 | -907.05 | 25,467 | 9,532 | 5,866 |
Change in Accounts Receivable | -3,374 | -3,878 | -7,454 | -7,901 | 1,433 | -3,480 |
Change in Inventory | -12,266 | -11,132 | 186.91 | -5,675 | 1,195 | -2,639 |
Change in Accounts Payable | 48.91 | 1,753 | -70.57 | 433.75 | 24.39 | 398.27 |
Change in Other Net Operating Assets | -691.33 | -925.88 | 804.17 | 340.48 | 1,450 | 771.63 |
Operating Cash Flow | -1,287 | 2,384 | 5,439 | -1,286 | 7,784 | 2,676 |
Operating Cash Flow Growth | - | -56.16% | - | - | 190.93% | 6.03% |
Capital Expenditures | -652.9 | -918.7 | -2,266 | -9,922 | -30,750 | -4,339 |
Sale of Property, Plant & Equipment | 28.28 | 28.28 | 80 | 190.25 | 46.58 | 5.3 |
Sale (Purchase) of Intangibles | -1,803 | -1,865 | -985.79 | -2,034 | -3,260 | -582.75 |
Investment in Securities | 1,500 | 1,500 | 6,490 | -3,498 | 1,501 | -550 |
Other Investing Activities | 368.19 | 365.88 | -58.67 | -20.38 | 2,077 | -2,254 |
Investing Cash Flow | -559.59 | -889.45 | 3,260 | -15,284 | -30,385 | -7,721 |
Short-Term Debt Issued | - | - | - | 389.68 | 1,169 | - |
Long-Term Debt Issued | - | - | 11,200 | 33,300 | 49,779 | 20,500 |
Total Debt Issued | - | - | 11,200 | 33,690 | 50,948 | 20,500 |
Short-Term Debt Repaid | - | - | - | -2,338 | - | - |
Long-Term Debt Repaid | - | -751.26 | -2,633 | -30,880 | -20,428 | -983.48 |
Total Debt Repaid | -20,754 | -751.26 | -2,633 | -33,218 | -20,428 | -983.48 |
Net Debt Issued (Repaid) | -20,754 | -751.26 | 8,567 | 471.8 | 30,521 | 19,517 |
Other Financing Activities | 268.65 | 267.31 | 284.59 | 1,797 | -180.05 | 51.18 |
Financing Cash Flow | -20,486 | -483.95 | 8,852 | 2,269 | 30,340 | 19,568 |
Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | - | - | 0 |
Net Cash Flow | -22,332 | 1,011 | 17,551 | -14,302 | 7,739 | 14,523 |
Free Cash Flow | -1,940 | 1,466 | 3,173 | -11,208 | -22,966 | -1,664 |
Free Cash Flow Growth | - | -53.81% | - | - | - | - |
Free Cash Flow Margin | -1.13% | 0.86% | 1.90% | -7.43% | -20.90% | -1.72% |
Free Cash Flow Per Share | -91.07 | 67.29 | 152.58 | -519.12 | -1234.84 | -110.74 |
Cash Interest Paid | 1,537 | 1,544 | 2,112 | 1,718 | 1,112 | 297.81 |
Cash Income Tax Paid | 764.89 | 131.67 | 2,124 | 52.99 | 866.9 | 209.36 |
Levered Free Cash Flow | -10,260 | -7,432 | -6,644 | -8,116 | -23,020 | -6,110 |
Unlevered Free Cash Flow | -7,662 | -4,834 | -3,979 | -5,922 | -21,944 | -5,929 |
Change in Working Capital | -16,282 | -14,183 | -6,534 | -12,802 | 4,102 | -4,950 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.